Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TIAM1
REST API REST API
Homo sapiens
TIAM1 is differentially expressed in 325 experiments: 171 organism parts: cerebellum, amygdala, ... (169 more);, 245 disease states: normal, colon carcinoma, ... (243 more);, 123 cell types 504 cell lines 35 compound treatments and 80 other conditions.
Orthologs TIAM1 (Gallus gallus)   TIAM1 (Bos taurus)   TIAM1 (1 of 2) (Danio rerio)   tiam1 (Danio rerio)   D3ZTB8_RAT (Rattus norvegicus)   Tiam1 (Mus musculus)   sif (Drosophila melanogaster)   CDC24 (Saccharomyces cerevisiae)   tiam1 (Xenopus laevis)   TIAM1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, receptor signaling protein activity, protein binding, apoptosis, intracellular, cell-cell junction, regulation of catalytic activity, phospholipid binding, ephrin receptor binding, regulation of Rho protein signal transduction, guanyl-nucleotide exchange factor activity, small GTPase mediated signal transduction, regulation of small GTPase mediated signal transduction, Rho guanyl-nucleotide exchange factor activity, signal transduction, positive regulation of axonogenesis, ephrin receptor signaling pathway, induction of apoptosis by extracellular signals, nerve growth factor receptor signaling pathway, intracellular signal transduction
InterPro Term PDZ/DHR/GLGF, Pleckstrin_homology, DH-domain, Raf-like_ras-bd
UniProt Accession Q13009, C9JMB5, F5GZ53, E9PD83
Search EB-eye ENSG00000156299
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-MEXP-433, E-GEOD-7540, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-18005, E-GEOD-2450, ... (49 experiments)

Factor Value U/D Experiments
SW480
4
E-MTAB-37, E-GEOD-18005, E-MEXP-1014, E-GEOD-2509
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-GEOD-15460, E-MTAB-37
HCC2157
2
E-MTAB-37, E-MTAB-62
K562
2
E-MTAB-37, E-GEOD-24147
498 more value(s).


Cell type

studied in E-MEXP-2426, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (60 experiments)

Factor Value U/D Experiments
stromal cell
3
E-MEXP-2034, E-GEOD-1460, E-MEXP-1327
bronchial epithelial
2
E-AFMX-5, E-MTAB-25
dendritic cell
2
E-GEOD-360, E-GEOD-3982
macrophage
2
E-GEOD-22373, E-GEOD-360
2
2
E-TABM-130, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
117 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-GEOD-16363, ... (75 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-MTAB-62, E-MTAB-37, E-GEOD-3726, E-MTAB-57
control
4
E-GEOD-21912, E-GEOD-16363, E-GEOD-8121, E-GEOD-20602
lung adenocarcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-2514
ulcerative colitis
2
E-GEOD-3365, E-MTAB-62
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
cervical carcinoma
2
E-MTAB-62, E-GEOD-5823
239 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-4668, E-GEOD-5741, E-GEOD-15205, E-GEOD-5824, ... (22 experiments)

Factor Value U/D Experiments
17beta-estradiol
1
2
3
E-GEOD-4006, E-GEOD-4668, E-GEOD-2292
sapphyrin PCI-2054
1
E-GEOD-6400
ethanol
1
E-GEOD-3113
ponasterone A
1
E-GEOD-3113
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
water
1
E-MEXP-1372
29 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-860, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-2509, E-TABM-147, E-GEOD-21138, E-GEOD-3013 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (9 experiments)

Genotype
studied in E-GEOD-1923, E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-TABM-321, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-7011, E-TABM-127, E-MEXP-1446, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-974, E-MEXP-1956, ... (35 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-17400, E-GEOD-512 ... (5 experiments)

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-1493, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-1422, E-MEXP-1509, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246, E-GEOD-13818, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.407 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM